How to buy LogicBio Therapeutics stock - 21 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy LogicBio Therapeutics stock

Own LogicBio Therapeutics stock in just a few minutes.

LogicBio Therapeutics, Inc is a biotechnology business based in the US. LogicBio Therapeutics shares (LOGC) are listed on the NASDAQ and all prices are listed in US Dollars. LogicBio Therapeutics employs 39 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in LogicBio Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LOGC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

LogicBio Therapeutics share price

Use our graph to track the performance of LOGC stocks over time.

LogicBio Therapeutics shares at a glance

Information last updated 2021-04-15.
52-week range$5.00 - $10.00
50-day moving average $7.61
200-day moving average $7.42
Wall St. target price$20.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.55

Buy LogicBio Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy LogicBio Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

LogicBio Therapeutics financials

Revenue TTM $3.5 million
Gross profit TTM $3.5 million
Return on assets TTM -28.9%
Return on equity TTM -62.91%
Profit margin 0%
Book value $1.93
Market capitalisation $200.2 million

TTM: trailing 12 months

Shorting LogicBio Therapeutics shares

There are currently 832,912 LogicBio Therapeutics shares held short by investors – that's known as LogicBio Therapeutics's "short interest". This figure is 1% up from 824,401 last month.

There are a few different ways that this level of interest in shorting LogicBio Therapeutics shares can be evaluated.

LogicBio Therapeutics's "short interest ratio" (SIR)

LogicBio Therapeutics's "short interest ratio" (SIR) is the quantity of LogicBio Therapeutics shares currently shorted divided by the average quantity of LogicBio Therapeutics shares traded daily (recently around 134340.64516129). LogicBio Therapeutics's SIR currently stands at 6.2. In other words for every 100,000 LogicBio Therapeutics shares traded daily on the market, roughly 6200 shares are currently held short.

However LogicBio Therapeutics's short interest can also be evaluated against the total number of LogicBio Therapeutics shares, or, against the total number of tradable LogicBio Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case LogicBio Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 LogicBio Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0391% of the tradable shares (for every 100,000 tradable LogicBio Therapeutics shares, roughly 39 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against LogicBio Therapeutics.

Find out more about how you can short LogicBio Therapeutics stock.

LogicBio Therapeutics share dividends

We're not expecting LogicBio Therapeutics to pay a dividend over the next 12 months.

LogicBio Therapeutics share price volatility

Over the last 12 months, LogicBio Therapeutics's shares have ranged in value from as little as $5 up to $10. A popular way to gauge a stock's volatility is its "beta".

LOGC.US volatility(beta: 1.26)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while LogicBio Therapeutics's is 1.2587. This would suggest that LogicBio Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

LogicBio Therapeutics overview

LogicBio Therapeutics, Inc. , a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as two additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop next-generation capsids for gene therapy and editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site